Welldoc, a leader in AI-powered health technology, has expanded its digital health platform to include comprehensive support for chronic kidney disease (CKD) and metabolic dysfunction-associated steatohepatitis (MASH). This enhancement builds on Welldoc’s existing expertise in cardiometabolic care, particularly in weight management with and without GLP-1 therapies, now extending personalized, AI-driven coaching, education, and health tracking for these often underdiagnosed conditions. The expansion comes at a critical time as research shows growing evidence that GLP-1 therapies offer benefits beyond glucose control, including protection for the kidneys and liver. The FLOW Trial demonstrated that semaglutide reduced the risk of kidney-related events and cardiovascular death by 24% in patients with type 2 diabetes and chronic kidney disease. Similarly, interim results from the ESSENCE Trial showed that semaglutide led to resolution of MASH without worsening fibrosis in 62.9% of patients with fibrosis stage F2 or F3. Dr. Mansur Shomali, Welldoc’s Chief Medical Officer and a practicing endocrinologist, emphasized the interconnected nature of cardiometabolic conditions. “These diseases frequently coexist and are often undetected until advanced stages,” he said. “Our AI platform enables personalized, integrated care that addresses root causes and supports both patients and providers in managing multiple comorbidities in a unified way.” Weight management remains a cornerstone of MASH treatment. Dr. Holly Lofton, Scientific Advisor at Welldoc and Director of the Medical Weight Management Program at NYU Langone Health, noted that obesity is a primary driver of MASH progression. “The most effective interventions involve sustained lifestyle changes and weight loss,” she said. “By integrating MASH support into a broader cardiometabolic platform, Welldoc delivers a powerful, efficient tool to help patients take meaningful steps to slow liver disease progression.” The inclusion of CKD and MASH support addresses significant public health challenges. According to the CDC, nearly 1 in 7 adults in the U.S. has CKD, with rising costs tied to treatment and complications. MASH, now the most common form of chronic liver disease, is projected to become the leading cause of liver transplants by 2030. Welldoc’s platform is FDA-cleared and backed by more than 90 clinical publications. With over 11,000 510(k) clearances for diabetes-related functions and a portfolio of 50+ patents, the company continues to lead in AI-driven digital health innovation. Recognized as the “Best Overall Digital Health Company” for three consecutive years and a winner of the 2024 Healthcare AI Impact Awards, Welldoc partners with health plans, providers, and employers to improve outcomes and reduce costs. The company’s platform now offers integrated support for prediabetes, diabetes, hypertension, heart failure, obesity, weight management, CKD, MASH, mental wellbeing, and sleep. For more information, visit www.welldoc.com. Follow Welldoc on LinkedIn and X.